Type 1 diabetes presents as a potentially life-threatening autoimmune disorder characterized by the destruction of pancreatic beta cells through T-cell-mediated mechanisms, leading to impaired insulin synthesis and secretion. Positioned as a leader in type 1 diabetes diagnostics, our company offers a comprehensive range of diagnostic solutions, encompassing IVD products, point-of-care testing, and companion diagnostic development services.
Overview of Type 1 Diabetes
Type 1 diabetes manifests as a chronic immune-mediated condition marked by the destruction of insulin-producing cells, resulting in hyperglycemia and ketosis. Incidence rates in regions such as China, Asia, and South America typically range from 1 to 3 cases per 100,000 individuals annually.
The development of beta cell autoantibodies is believed to occur following exposure to environmental triggers in genetically susceptible individuals, disrupting immune regulation. Ongoing research in type 1 diabetes aims to identify factors associated with beta cell destruction, with genetic, infectious, dietary, and humoral factors being of primary interest. Notably, genetic variations within the human leukocyte antigen (HLA) region contribute significantly to the genetic predisposition to type 1 diabetes.
Fig.1 Environmental factors associated with type 1 diabetes. (Akil, A. A., et al., 2021)
Biomarkers Development for Type 1 Diabetes
The ongoing advancements in biomarker development for type 1 diabetes show great potential in enhancing early detection, monitoring disease progression, and customizing personalized therapies. Key focal points in biomarker development for type 1 diabetes include autoantibodies and genetic markers.
Autoantibodies
The presence and combination of autoantibodies targeting beta cells are pivotal for predicting type 1 diabetes advancement. Notably, five types of islet autoantibodies have been identified, including antibodies against insulin (IAA), insulinoma-associated antigen-2 (IA-2), glutamic acid decarboxylase (GAD), zinc transporter 8 (ZnT8), and islet cell antibodies (ICA).
Genetic Markers
Genetic markers, particularly within the HLA complex involved in antigen presentation, play a crucial role in type 1 diabetes pathogenesis, contributing significantly to the genetic risk profile. These genetic indicators shed light on disease mechanisms and aid in assessing risk, especially for individuals with a familial history of type 1 diabetes.
IVD Kits for Type 1 Diabetes
| Kits |
Applications |
Method of detection |
| Insulin Autoantibody Assay kit |
Measure autoantibodies to human insulin |
ELISA |
| ZNT8 Autoantibody ELISA Kit |
Detection of ZNT8 autoantibody in serum, plasma, urine, tissue homogenates, or cell culture supernates |
ELISA |
| HLA Gene Sequencing Kit |
Perform a comprehensive analysis of the HLA gene sequence |
NGS |
| HLA PCR Test Kit (Real-time) |
Detection of HLA gene |
PCR |
Our Services
With a robust portfolio of cutting-edge technologies and a dedicated focus on biomarker discovery, genetic screening, and personalized therapy, we excel in developing IVD products. Additionally, we offer point-of-care testing and companion diagnostic development solutions to accelerate timely diagnosis and customized therapies for type 1 diabetes.
Our proficiency in identifying novel biomarkers, harnessing advanced genetic testing methodologies, and leveraging data analytics methods enables us to deliver state-of-the-art diagnostic solutions for type 1 diabetes. If you are interested in our services, please don't hesitate to reach out for further information and pricing details.
Reference
- Akil, Ammira Al-Shabeeb et al. "Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era." Journal of translational medicine 19.1 (2021): 137.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
